Article
Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Hematology (Amsterdam, Netherlands) - 1 Jul 2013
Bedewy Ahmed M L, El-Maghraby Shereen M
Abstract excerpt
BACKGROUND: Imatinib has so far been the first-choice treatment in chronic myeloid leukemia (CML) with excellent results. However, only a proportion of patients achieve major molecular response. Hence, the need to find whether there are some factors that affect the response to treatment is essential. This study aimed to investigate the allele and genotype frequencies of single nucleotide polymorphisms (SNPs) of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.